Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express Inc (PETS), America's largest online pet pharmacy, provides this centralized hub for official corporate communications and market-moving developments. Access verified press releases, SEC filings, and strategic announcements from the nation's leading direct-to-consumer pet medication provider.
Investors and industry observers will find comprehensive coverage of financial results, regulatory updates, product innovations, and partnership agreements. Our curated news feed tracks material events impacting PETS' position in the $100B pet healthcare market, including prescription medication approvals and e-commerce platform enhancements.
Key updates include quarterly earnings disclosures, FDA compliance announcements, and distribution network expansions. All content is sourced directly from company filings and official statements to ensure regulatory compliance and factual accuracy.
Bookmark this page for real-time access to PETS' corporate communications, including 8-K filings detailing material events and 10-K annual reports. Check regularly for updates on the company's mission to deliver affordable pet healthcare through its innovative online pharmacy model.
Cardone Ventures submitted an unsolicited, non-binding all-cash proposal to acquire PetMed Express (Nasdaq: PETS) for $4.25 per share, implying an equity value of approximately $89 million on December 16, 2025.
The proposal is not subject to a financing contingency and is led by Brandon Dawson, Natalie Dawson, and Grant Cardone. Cardone Ventures highlights operational experience including scaling its firm to about $225 million in revenue in five years and managing over $2 billion in assets under management; Grant Cardone is described as managing over $5 billion of assets.
The offer is non-binding and conditioned on customary due diligence, a definitive agreement, and required approvals, and there is no assurance a transaction will be completed.
PetMeds (Nasdaq: PETS) confirmed receipt on Dec 11, 2025 of an unsolicited, non-binding proposal from SilverCape Investments Limited to acquire all outstanding shares for $4.00 per share in cash. The offer is subject to due diligence and execution of a definitive agreement but is not conditioned on financing. SilverCape publicly disclosed the proposal in an amendment to its Schedule 13D filed with the SEC on Dec 11, 2025. The PetMeds board, with financial and legal advisers, will review the proposal consistent with its fiduciary duties. The company said this letter is not a formal offer capable of acceptance and stockholders need take no action at this time.
PetMeds (Nasdaq: PETS) unveiled its 2025 Holiday Collection on December 10, 2025: a curated assortment of wellness-focused gifts for pets and pet parents emphasizing health, safety, and everyday comfort.
The collection highlights grooming items, first-aid and screening tests (including an at-home cancer urine test and multiple DNA tests), toys, treats, cat monitoring devices, equine grooming and supplements, and natural pest-repellent collars. The Holiday Giftable Essentials Collection is available now at PetMeds.com with fast shipping and subscription options for select items.
PetMeds (Nasdaq: PETS) announced that its Board unanimously approved an amendment extending the company’s existing shareholder rights plan by one year, moving the expiration from December 2, 2025 to December 2, 2026. All other terms remain unchanged.
The Board said the extension is intended to protect shareholders while it believes the stock does not reflect the company’s inherent value and because of recent significant accumulations of company common stock by certain shareholders. The Rights Plan is intended to ensure fair treatment and to guard against acquisitions without payment of an appropriate control premium. A Form 8-K will provide further details.
PetMed Express (Nasdaq: PETS) announced preliminary fiscal Q2 2026 results and filed a Form 12b-25 notifying the SEC of a late 10-Q filing for the quarter ended September 30, 2025. The Company estimates Q2 net sales of $43.4M–$44.5M versus $58.0M in the prior year and six-month net sales of $94.5M–$95.6M versus $124.3M prior. The company reported $36.1M cash and no debt as of September 30, 2025.
The Company cannot yet estimate operating or net income while it analyzes the timing and amount of an anticipated goodwill impairment. Nasdaq sent a notice of non-compliance; the company must update its plan by November 28, 2025, and any Nasdaq exception may be limited to December 29, 2025. The notice does not have an immediate effect on the stock listing.
PetMed Express (Nasdaq: PETS) appointed James LaCamp to its Board effective immediately and named him Chair of the Audit Committee, effective October 30, 2025. Mr. LaCamp qualifies as an audit committee financial expert and brings nearly two decades of finance, accounting, and audit experience including 12+ years as an audit partner at Deloitte.
The Board now has six directors, five independent, and has added four directors since 2024 as part of ongoing board refreshment.
PetMeds (NASDAQ: PETS) filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
Key fiscal 2025 results: net sales $227.0 million (below prior preliminary range of $231.6–$233.6 million), net loss $6.3 million (wider than prior preliminary $4.5–$5.0 million), and cash $54.7 million with no debt. The company recorded a $1.2 million non-cash intangible impairment and restated promotional sales reimbursements from revenue to cost of sales, which the company says did not affect net income.
Management said it will file Form 10-Q for Q1 ended June 30, 2025 and subsequent quarterly filings "as soon as practicable" but gave no firm dates.
PetMed Express (NASDAQ: PETS) announced a September 9, 2025 award of 15,000 restricted common shares to Ali Khan upon his hiring as Chief Information Security Officer. The grant was made under the 2024 Inducement Incentive Plan and designated a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The shares vest in equal one-third increments on each of the first three anniversaries of the vesting commencement date, August 20, 2025, subject to continued employment.
PetMed Express (NASDAQ: PETS) announced significant leadership changes as CEO Sandra Campos and CFO Robyn D'Elia have resigned from their positions. Board Chair Leslie C.G. Campbell has been appointed as Interim CEO, while Chief Accounting Officer Douglas Krulik will serve as Interim Principal Financial Officer.
The departing executives will receive 13 months of base salary continuation and accelerated vesting of certain restricted stock units as severance, along with providing consulting services for three months. The company has initiated a search for permanent CEO and CFO positions. The Board has been restructured with Justin Mennen appointed as Lead Independent Director, while Peter Batushansky and Leah Solivan will chair the Audit and Compensation committees respectively.
PetMeds (NASDAQ: PETS) has partnered with myBalto Foundation for their "Top of the Class" fundraising drive, successfully raising nearly $45,000 to help pet owners cover emergency veterinary costs. The initiative aims to support myBalto's Angel Fund program, which assists veterinary hospitals in providing financial aid to pet parents facing hardships.
As part of the partnership, PetMeds offered 25% discounts to donors to encourage community participation. The myBalto Foundation provides veterinary hospitals with free Angel Funds, eliminating administrative burdens while enabling quick financial support for pet owners during emergency situations.
FAQ
What is the current stock price of Petmed Express (PETS)?
What is the market cap of Petmed Express (PETS)?
